ATG Dosing for GVHD Prevention

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 2
Enrollment
56 patients (estimated)
Sponsors
University of Alabama at Birmingham
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1835
NCT Identifier
NCT06265584

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.